Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease

In order to solve the problem of long-term (>9 months) efficacy in the treatment of Alzheimer''s disease (AD) by conventional therapy (CT), a staged and multiply-targeted sequential therapy based on the evolvement of patterns (STEP) was developed. Its main innovations include: (1) the time order of evolution of patterns defined by Chinese medicine (CM) in AD was found, that is, "the orderly pattern evolution starting from Shen (Kidney) deficiency, progressing to phlegm, stasis and fire, and worsening to severe toxin as well as functional collapse"; (2) the cascade hypothesis of Shen deficiency in AD and its sequential therapy based on Shen-reinforcing was proposed, that is, "reinforcing Shen in the early stage and throughout the whole process, resolving phlegm, activating blood and purging fire in the middle stage, detoxifying and replenishing vitality to stop the collapse in the advanced stage", and through meta-analysis, clinical drug use was optimized, thus the leap from "inferential selection" to "evidence-based selection" was realized; (3) the STEP regimen combined with CT maintained cognitive and behavioral stability in AD patients for at least 12 months, with cognitive enhancement and behavioral synergy after 9 months, and cognitive benefit was superior to CT at 9, 12, 15, 18, 21, and 24 months, respectively. The 2-year cognitive improvement rate was increased by 25.64% (P=0.020) and the cognitive deterioration rate was decreased by 48.71% (P=0.000). Among them, the cognitive and functional benefits of Shen-reinforcing therapy for very early AD (350 cases) for 1 year were better than the placebo (P<0.001), and the dementia conversion rate was reduced by 8.85% (P=0.002). The behavioral symptomatic relief of patients with vascular dementia received fire-purging therapy (540 cases) was superior to those received CT (P=0.016). These data suggested that the STEP regimen has synergistic effects on CTs at least in terms of cognitive benefit, and the earlier the use, the greater the benefit will have. Therefore, the STEP regimen should be considered as one of the clinical options, particularly for the dearth of effective pharmaceutical or immunological interventions that are currently available for AD.     

肝门胆管癌的动态增强CT诊断

目的评价螺旋CT对肝门胆管癌的诊断价值。方法13例肝门胆管癌行螺旋CT平扫及动态增强扫描,并与手术及病理对照分析。结果11例平扫表现为肝门区低密度软组织肿块;2例表现为肝门区胆管不规则增厚,管腔狭窄。增强扫描13例有延迟强化。结论螺旋CT扫描对肝门胆管癌的诊断具有重要意义。     

肝癌间质及癌旁病变的病理分析

目的　研究肝癌间质及癌旁病变的临床病理意义。方法　在 2 0例肝癌组织标本中取 45个癌结节 ,分别在癌结节中间、癌旁肝组织等部位取组织 4块 ,连续切片 ,显微镜下观察。结果　 19个结节有完整窦内皮细胞围绕癌巢 ,其中癌结节肉眼小于3cm者 13个 ,大于 3cm者 6个。 2 6个癌结节无完整窦内皮细胞围绕癌巢 ,其中癌结节直径大于 3cm者 2 4个 ,小于 3cm者 2个。2 0例中有 13例合并肝硬化 ,17例有乙型肝炎病毒感染和HBsAg阳性。 结论　病理连续切片 ,显微镜下观察肝癌间质及癌旁病变是预测肝癌患者预后的重要病理学指标     

肛直肠抑制反射时门静脉血中P物质变化

目的探讨肛直肠抑制反射（RAIR）时门静脉血中P物质（SP）的变化规律及外源性内脏神经对其变化的影响。方法将实验大白鼠分为7组，其中6组先按去与不去直肠肛管外源性内脏神经支配而分为不去神经和去神经两大组，每组中又按Foley导管上气囊置入直肠腔中的位置分为2、4、6cm组；同时再设1个对照组，将Foley导管置入直肠腔中，但不注水扩张球囊。检测并比较在直肠腔内刺激后，各组门静脉血中的SP值及变化情况。结果去神经组中2、4cm组与不去神经组之间及对照组之间，门静脉血中SP值变化比较，P〉0．05，差异无统计学意义。不去神经组中的6cm组与对照组及去神经组中2cm和4cm组之间SP值比较，P〈0．01，差异有统计学意义；去神经组和不去神经组中的6cm组之间SP值比较，P〈0．01，差异有统计学意义。结论直肠腔内上部的刺激不引出RAIR可能与该部位的刺激使内括约肌兴奋性递质（SP）的释放有关；外源性内脏神经对RAIR中门静脉血的SP变化有调控作用。     

游走火罐配透刺、艾灸治疗周围性面瘫35例

周围性面瘫,多是由面神经炎引起面神经缺血、水肿导致的面肌瘫痪[1].笔者近年在沙特阿拉伯工作期间,有感于面部按摩疗法在周围性面瘫康复中的广泛应用,以面部游走火罐配合针灸疗法治疗本病35例,均取得了较好的疗效.现总结如下.     

灰关联分析应用于因素分析时关联度指标的改进

本文指出在应用灰关联分析进行因素分析时传统的关联度计算方法的不足，并提出采用新的关联度指标来表示因素之间的关联关系，同时给出了实例介绍计算方法。     

常用消毒剂及自来水对弓形虫速殖子活力的影响

目的了解常用消毒剂及自来水对弓形虫速殖子活力的影响。方法将各种消毒剂分别加入等体积含弓形虫速殖子的小鼠腹水中，在不同时间内观察虫体胎盘蓝（trypanblue）着色率及活动率，并将经消毒剂处理不同时间的速殖予接种昆明鼠，观察速殖子能否在接种鼠体内复苏繁殖，导致小鼠死亡。用类似方法观察自来水时速殖子的影响。结果除甲醛个速殖子在常用浓度的不同消毒剂中，lmin月台盘蓝着色率均为100％，活动率为0。经消毒剂处理1min的速殖子接种小鼠后，各组接种鼠（包括甲醛处理组）无一死亡。经自来水处理4h的速殖子接种小鼠后仍能在小鼠体内复苏繁殖，小鼠于接种1wk内全部死亡。结论弓形虫速殖子对常用消毒剂均很敏感；而在自来水中途殖子可保持感染力4h以上。     

铁路系统医院136篇口腔修复、正畸学论文的统计分析

通过对铁路系统医院１３６篇口腔修复、正畸学论文的统计分析，来评价医院口腔修复、正畸的科研水平，同时也揭示了科研工作中存在的问题。指出只有加强科研协作、扩大学术交流、增加科研投入，提高科研水平，使科研成果更趋完善。     

Angiotensin I conversion and coronary constriction by angiotensin II in ischemic and hypoxic isolated rat hearts.

Dose-response curves of angiotensin I (AI, 1.0-1000.0 pmol) and angiotensin II (AII, 1.25-1250.00 pmol) were obtained in isolated rat hearts subjected to control conditions, mild hypoxia (PO2 = 145 mm Hg), reoxygenation, ischemic (perfusion pressure = 35 mm Hg) and reperfusion. Both AI and AII caused dose-dependent coronary flow (CF) of 26 +/- 3 and 27 +/- 2%, respectively. The effects of both AI and AII were substantially attenuated during hypoxia, but were fully restored upon reoxygenation. During ischemia, the effect of AII was unaltered while the effect of AI was enhanced compared to the control (P less than 0.05). This enhancement was reversible on reperfusion. Cardiac conversion of AI, calculated from ED50 values for AI and AII, was significantly increased during ischemia (P less than 0.05). Infusion of saralasin (0.5-5.0 micrograms/min) did not increase CF in any of the groups. We conclude that (1) the coronary vasoconstrictive effect of AII is preserved in ischemia but attenuated in hypoxia and (2) cardiac conversion of AI to AII is enhanced in hearts injured by ischemia.